vs

Side-by-side financial comparison of Vivos Therapeutics, Inc. (VVOS) and Expion360 Inc. (XPON). Click either name above to swap in a different company.

Vivos Therapeutics, Inc. is the larger business by last-quarter revenue ($3.8M vs $2.2M, roughly 1.7× Expion360 Inc.). Vivos Therapeutics, Inc. runs the higher net margin — -180.3% vs -199.9%, a 19.7% gap on every dollar of revenue. On growth, Expion360 Inc. posted the faster year-over-year revenue change (11.8% vs 3.4%). Over the past eight quarters, Expion360 Inc.'s revenue compounded faster (51.1% CAGR vs 5.8%).

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

Expion360 Inc. is a provider of high-performance lithium iron phosphate (LFP) battery solutions and supporting energy storage products. Its core customer segments cover recreational vehicle owners, marine users, off-grid lifestyle enthusiasts and residential users across the U.S. market, delivering safe, durable and low-carbon energy storage options.

VVOS vs XPON — Head-to-Head

Bigger by revenue
VVOS
VVOS
1.7× larger
VVOS
$3.8M
$2.2M
XPON
Growing faster (revenue YoY)
XPON
XPON
+8.4% gap
XPON
11.8%
3.4%
VVOS
Higher net margin
VVOS
VVOS
19.7% more per $
VVOS
-180.3%
-199.9%
XPON
Faster 2-yr revenue CAGR
XPON
XPON
Annualised
XPON
51.1%
5.8%
VVOS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
VVOS
VVOS
XPON
XPON
Revenue
$3.8M
$2.2M
Net Profit
$-6.9M
$-4.4M
Gross Margin
78.1%
-14.8%
Operating Margin
-166.8%
-234.4%
Net Margin
-180.3%
-199.9%
Revenue YoY
3.4%
11.8%
Net Profit YoY
-143.8%
-1663.2%
EPS (diluted)
$-0.58
$-0.45

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
VVOS
VVOS
XPON
XPON
Q4 25
$3.8M
$2.2M
Q3 25
$6.8M
$2.4M
Q2 25
$3.8M
$3.0M
Q1 25
$3.0M
$2.0M
Q4 24
$3.7M
$2.0M
Q3 24
$3.9M
$1.4M
Q2 24
$4.1M
$1.3M
Q1 24
$3.4M
$971.9K
Net Profit
VVOS
VVOS
XPON
XPON
Q4 25
$-6.9M
$-4.4M
Q3 25
$-5.4M
$722.8K
Q2 25
$-5.0M
$-1.4M
Q1 25
$-3.9M
$-1.2M
Q4 24
$-2.8M
$-251.6K
Q3 24
$-2.6M
$-8.8M
Q2 24
$-1.9M
$-2.2M
Q1 24
$-3.8M
$-2.2M
Gross Margin
VVOS
VVOS
XPON
XPON
Q4 25
78.1%
-14.8%
Q3 25
58.0%
22.7%
Q2 25
55.2%
20.8%
Q1 25
50.0%
24.5%
Q4 24
56.7%
22.1%
Q3 24
60.5%
12.1%
Q2 24
65.4%
25.5%
Q1 24
56.7%
22.9%
Operating Margin
VVOS
VVOS
XPON
XPON
Q4 25
-166.8%
-234.4%
Q3 25
-69.8%
-125.4%
Q2 25
-127.4%
-45.2%
Q1 25
-129.9%
-56.0%
Q4 24
-75.9%
-59.5%
Q3 24
-68.5%
-138.7%
Q2 24
-47.8%
-131.4%
Q1 24
-110.7%
-202.4%
Net Margin
VVOS
VVOS
XPON
XPON
Q4 25
-180.3%
-199.9%
Q3 25
-79.6%
30.2%
Q2 25
-131.2%
-45.8%
Q1 25
-128.1%
-56.2%
Q4 24
-76.4%
-12.7%
Q3 24
-67.8%
-634.4%
Q2 24
-47.6%
-173.7%
Q1 24
-110.1%
-225.6%
EPS (diluted)
VVOS
VVOS
XPON
XPON
Q4 25
$-0.58
$-0.45
Q3 25
$-0.49
$0.10
Q2 25
$-0.55
$-0.41
Q1 25
$-0.45
$-0.37
Q4 24
$0.41
$65.02
Q3 24
$-0.40
$-24.55
Q2 24
$-0.60
$-30.20
Q1 24
$-1.63
$-31.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
VVOS
VVOS
XPON
XPON
Cash + ST InvestmentsLiquidity on hand
$2.0M
$3.0M
Total DebtLower is stronger
$2.9M
$197.2K
Stockholders' EquityBook value
$-1.5M
$6.5M
Total Assets
$25.2M
$8.1M
Debt / EquityLower = less leverage
0.03×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
VVOS
VVOS
XPON
XPON
Q4 25
$2.0M
$3.0M
Q3 25
$3.1M
$4.3M
Q2 25
$4.4M
$684.9K
Q1 25
$2.3M
$1.1M
Q4 24
$6.3M
$547.6K
Q3 24
$6.3M
$3.3M
Q2 24
$6.9M
$902.3K
Q1 24
$2.6M
$2.3M
Total Debt
VVOS
VVOS
XPON
XPON
Q4 25
$2.9M
$197.2K
Q3 25
$205.6K
Q2 25
$213.6K
Q1 25
$221.8K
Q4 24
$1.2M
$230.2K
Q3 24
$1.2M
$239.9K
Q2 24
$1.2M
$247.7K
Q1 24
$255.4K
Stockholders' Equity
VVOS
VVOS
XPON
XPON
Q4 25
$-1.5M
$6.5M
Q3 25
$2.5M
$9.0M
Q2 25
$4.6M
$2.1M
Q1 25
$4.4M
$3.2M
Q4 24
$8.0M
$2.5M
Q3 24
$7.7M
$2.5M
Q2 24
$6.3M
$2.5M
Q1 24
$582.0K
$3.7M
Total Assets
VVOS
VVOS
XPON
XPON
Q4 25
$25.2M
$8.1M
Q3 25
$25.6M
$10.7M
Q2 25
$26.0M
$8.6M
Q1 25
$11.3M
$9.2M
Q4 24
$15.3M
$9.1M
Q3 24
$15.3M
$10.1M
Q2 24
$15.8M
$8.8M
Q1 24
$11.8M
$10.0M
Debt / Equity
VVOS
VVOS
XPON
XPON
Q4 25
0.03×
Q3 25
0.02×
Q2 25
0.10×
Q1 25
0.07×
Q4 24
0.15×
0.09×
Q3 24
0.16×
0.09×
Q2 24
0.19×
0.10×
Q1 24
0.07×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
VVOS
VVOS
XPON
XPON
Operating Cash FlowLast quarter
$-3.8M
$-2.4M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-139.7%
Capex IntensityCapex / Revenue
40.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-17.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
VVOS
VVOS
XPON
XPON
Q4 25
$-3.8M
$-2.4M
Q3 25
$-4.2M
$-2.1M
Q2 25
$-3.5M
$-401.0K
Q1 25
$-3.8M
$-1.2M
Q4 24
$-2.9M
$-2.9M
Q3 24
$-4.2M
$-3.2M
Q2 24
$-3.0M
$-1.7M
Q1 24
$-2.5M
$-1.7M
Free Cash Flow
VVOS
VVOS
XPON
XPON
Q4 25
$-5.3M
Q3 25
$-4.2M
Q2 25
$-4.3M
Q1 25
$-3.9M
Q4 24
$-3.1M
Q3 24
$-4.4M
Q2 24
$-3.1M
Q1 24
$-2.7M
$-1.7M
FCF Margin
VVOS
VVOS
XPON
XPON
Q4 25
-139.7%
Q3 25
-62.6%
Q2 25
-111.6%
Q1 25
-129.9%
Q4 24
-84.0%
Q3 24
-113.4%
Q2 24
-76.7%
Q1 24
-78.0%
-173.1%
Capex Intensity
VVOS
VVOS
XPON
XPON
Q4 25
40.0%
Q3 25
1.2%
Q2 25
20.2%
Q1 25
4.0%
Q4 24
4.5%
Q3 24
5.0%
Q2 24
1.5%
Q1 24
4.4%
1.1%
Cash Conversion
VVOS
VVOS
XPON
XPON
Q4 25
Q3 25
-2.90×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

VVOS
VVOS

Services$3.2M84%
Products$594.0K16%

XPON
XPON

Segment breakdown not available.

Related Comparisons